Free Trial
→ Elon’s BIGGEST warning yet? (From Brownstone Research) (Ad)
NYSE:ZYME

Zymeworks 3/6/2024 Earnings Report

Zymeworks logo
$12.67 -0.43 (-3.28%)
Closing price 04:00 PM Eastern
Extended Trading
$12.66 -0.01 (-0.04%)
As of 04:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
ProfileEarnings HistoryForecast

Zymeworks EPS Results

Actual EPS
-$0.20
Consensus EPS
-$0.39
Beat/Miss
Beat by +$0.19
One Year Ago EPS
N/A

Zymeworks Revenue Results

Actual Revenue
$16.93 million
Expected Revenue
$18.32 million
Beat/Miss
Missed by -$1.39 million
YoY Revenue Growth
N/A

Zymeworks Announcement Details

Quarter
Date
3/6/2024
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Zymeworks' next earnings date is estimated for Wednesday, July 30, 2025, based on past reporting schedules.

Conference Call Resources

Conference Call Audio

Earnings Conference Call
Zymeworks
00:00 / 00:00
Powered by Quartr

Zymeworks Earnings Headlines

Zymeworks: Early-Stage Biotech Feel Despite Zanidatamab Advancements (Downgrade)
June 12 at 5:14 PM | seekingalpha.com
Zymeworks’ zanidatamab gains approval in China for biliary tract cancer
June 2, 2025 | msn.com
Why July 22nd Could Mean Big Changes for Social Security
In a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Social Security — and his plan is set to roll out July 22. What's coming next isn't about trimming waste.
June 13, 2025 | Altimetry (Ad)
Zymeworks’ Drug Gets Conditional Approval For Biliary Tract Cancer Treatment In China: Retail Sentiment Refuses To Budge
May 30, 2025 | msn.com
Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer
May 30, 2025 | globenewswire.com
Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences
May 22, 2025 | globenewswire.com
See More Zymeworks Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Zymeworks? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Zymeworks and other key companies, straight to your email.

About Zymeworks

Zymeworks (NYSE:ZYME), a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.

View Zymeworks Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles